A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors
Sign Up to like & getrecommendations! Published in 2020 at "mAbs"
DOI: 10.1080/19420862.2020.1773751
Abstract: ABSTRACT Hu14.18K322A is a humanized anti-GD2 monoclonal antibody with a single point mutation that reduces complement-mediated cytotoxicity, with a maximum tolerated dose (MTD) of 60 mg/m2 daily for 4 days in children with recurrent/refractory neuroblastoma.… read more here.
Keywords: humanized anti; anti gd2; schedule; patients osteosarcoma ... See more keywords